LINFOMAS Y TRASPLANTES
University of Sydney
Sídney, AustraliaPublicaciones en colaboración con investigadores/as de University of Sydney (8)
2023
2022
-
Romidepsin Plus CHOP Versus CHOP in Patients With Previously Untreated Peripheral T-Cell Lymphoma: Results of the Ro-CHOP Phase III Study (Conducted by LYSA)
Journal of clinical oncology : official journal of the American Society of Clinical Oncology, Vol. 40, Núm. 3, pp. 242-251
2021
2020
-
Lenalidomide maintenance for diffuse large B-cell lymphoma patients responding to R-CHOP: quality of life, dosing, and safety results from the randomised controlled REMARC study
British Journal of Haematology, Vol. 189, Núm. 1, pp. 84-96
2019
-
Randomized phase III study of alisertib or investigator’s choice (selected single agent) in patients with relapsed or refractory peripheral T-cell lymphoma ¨
Journal of Clinical Oncology
-
Sustained progression-free survival benefit of rituximab maintenance in patients with follicular lymphoma: Long-term results of the PRIMA study
Journal of Clinical Oncology, Vol. 37, Núm. 31, pp. 2815-2824
2018
-
Ibrutinib as treatment for patients with relapsed/refractory follicular lymphoma: Results from the open-label, multicenter, phase II DAWN study
Journal of Clinical Oncology, Vol. 36, Núm. 23, pp. 2405-2412
2017
-
Lenalidomide maintenance compared with placebo in responding elderly patients with diffuse large B-cell lymphoma treated with first-line rituximab plus cyclophosphamide, doxorubicin, vincristine, and prednisone
Journal of Clinical Oncology, Vol. 35, Núm. 22, pp. 2473-2481